Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens
<p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | Diagnostic Pathology |
Subjects: | |
Online Access: | http://www.diagnosticpathology.org/content/7/1/25 |
id |
doaj-2a6291557ffd459b8f8ef713bde40609 |
---|---|
record_format |
Article |
spelling |
doaj-2a6291557ffd459b8f8ef713bde406092020-11-24T21:40:24ZengBMCDiagnostic Pathology1746-15962012-03-01712510.1186/1746-1596-7-25Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimensKirby SeanSatoskar AnjaliBrodsky SergeyPope-Harman AmyNunley DavidHitchcock CharlesPelletier RonaldRoss PatrickNadasdy TiborShilo Konstantin<p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of immunosuppressive regimen and pulmonary complications.</p> <p>Methods</p> <p>A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25 to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were correlated with clinical findings including immunosuppressive medications.</p> <p>Results</p> <p>The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases), and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process. Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5% vs. 58.3%, <it>p </it>= 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary hemorrhage as the sole histological finding or in combination with other patterns.</p> <p>Conclusions</p> <p>Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.</p> <p>Virtual Slides</p> <p>The virtual slide(s) for this article can be found here: <url>http://www.diagnosticpathology.diagnomx.eu/vs/3320012126569395</url>.</p> http://www.diagnosticpathology.org/content/7/1/25Kidney transplantationPulmonary neoplasiaPulmonary hemorrhageMammalian target of rapamycin (mTOR) inhibitorsSirolimus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kirby Sean Satoskar Anjali Brodsky Sergey Pope-Harman Amy Nunley David Hitchcock Charles Pelletier Ronald Ross Patrick Nadasdy Tibor Shilo Konstantin |
spellingShingle |
Kirby Sean Satoskar Anjali Brodsky Sergey Pope-Harman Amy Nunley David Hitchcock Charles Pelletier Ronald Ross Patrick Nadasdy Tibor Shilo Konstantin Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens Diagnostic Pathology Kidney transplantation Pulmonary neoplasia Pulmonary hemorrhage Mammalian target of rapamycin (mTOR) inhibitors Sirolimus |
author_facet |
Kirby Sean Satoskar Anjali Brodsky Sergey Pope-Harman Amy Nunley David Hitchcock Charles Pelletier Ronald Ross Patrick Nadasdy Tibor Shilo Konstantin |
author_sort |
Kirby Sean |
title |
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
title_short |
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
title_full |
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
title_fullStr |
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
title_full_unstemmed |
Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
title_sort |
histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens |
publisher |
BMC |
series |
Diagnostic Pathology |
issn |
1746-1596 |
publishDate |
2012-03-01 |
description |
<p>Abstract</p> <p>Background</p> <p>After the introduction of novel effective immunosuppressive therapies, kidney transplantation became the treatment of choice for end stage renal disease. While these new therapies lead to better graft survival, they can also cause a variety of complications. Only small series or case reports describe pulmonary pathology in renal allograft recipients on mTOR inhibitor inclusive therapies. The goal of this study was to provide a systematic review of thoracic biopsies in kidney transplant recipients for possible association between a type of immunosuppressive regimen and pulmonary complications.</p> <p>Methods</p> <p>A laboratory database search revealed 28 of 2140 renal allograft recipients (18 males and 10 females, 25 to 77 years old, mean age 53 years) who required a biopsy for respiratory symptoms. The histological features were correlated with clinical findings including immunosuppressive medications.</p> <p>Results</p> <p>The incidence of neoplasia on lung biopsy was 0.4% (9 cases), which included 3 squamous cell carcinomas, 2 adenocarcinomas, 1 diffuse large B-cell lymphoma, 1 lymphomatoid granulomatosis, and 2 post transplant B-cell lymphoproliferative disorders. Diffuse parenchymal lung disease was identified in 0.4% (9 cases), and included 5 cases of pulmonary hemorrhage, 3 cases of organizing pneumonia and 1 case of pulmonary alveolar proteinosis. Five (0.2%) cases showed histological features indicative of a localized infectious process. Patients on sirolimus had neoplasia less frequently than patients on other immunosuppressive combinations (12.5% vs. 58.3%, <it>p </it>= 0.03). Lung biopsies in 4 of 5 patients with clinically suspected sirolimus toxicity revealed pulmonary hemorrhage as the sole histological finding or in combination with other patterns.</p> <p>Conclusions</p> <p>Our study documents a spectrum of neoplastic and non-neoplastic lesions in renal allograft recipients on current immunosuppressive therapies. Sirolimus inclusive regimens are associated with increased risk of pulmonary toxicity but may be beneficial in cases of posttransplant neoplasia.</p> <p>Virtual Slides</p> <p>The virtual slide(s) for this article can be found here: <url>http://www.diagnosticpathology.diagnomx.eu/vs/3320012126569395</url>.</p> |
topic |
Kidney transplantation Pulmonary neoplasia Pulmonary hemorrhage Mammalian target of rapamycin (mTOR) inhibitors Sirolimus |
url |
http://www.diagnosticpathology.org/content/7/1/25 |
work_keys_str_mv |
AT kirbysean histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT satoskaranjali histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT brodskysergey histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT popeharmanamy histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT nunleydavid histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT hitchcockcharles histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT pelletierronald histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT rosspatrick histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT nadasdytibor histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens AT shilokonstantin histologicalspectrumofpulmonarymanifestationsinkidneytransplantrecipientsonsirolimusinclusiveimmunosuppressiveregimens |
_version_ |
1725926087546896384 |